As expected, (R)-crizotinib (but not (S)-crizotinib) was more efficient in inducing apoptosis and ICD hallmarks (CALR exposure, ATP and HMGB1 release) when added to a human NSCLC cell line that is positive for the EML4-ALK fusion protein (H2228 cells) than when administered to cells that are negative for the ALK activating translocation (H1650 cells) (Fig. 2a–h). This evidence concerns the gene EML4 and non-small cell lung carcinoma.